Experts Sound Alarm: Popular Hair Loss Drug Linked to Suicide

A new review by Prof. Mayer Brezis alleges that finasteride, a widely used hair-loss drug, has been linked to depression and suicide for over two decades, with both original manufacturer Merck and the FDA failing to adequately address the accumulating evidence. The study, based on extensive global data, criticizes the delayed regulatory response and corporate inaction, raising significant concerns about pharmacovigilance, potential litigation risks for pharmaceutical companies, and the urgent need for reform in post-market drug monitoring, particularly for cosmetic medications.

Analysis

Prof. Mayer Brezis's review reveals a persistent, two-decade link between finasteride and severe psychiatric side effects, including depression and suicide, drawing on global adverse event reports and eight large-scale studies (2017-2023). This highlights a systemic failure in pharmacovigilance, as both Merck (MRK) and the FDA allegedly neglected accumulating evidence and delayed meaningful action despite early warnings from 2002. The FDA's 2011 acknowledgment of depression and 2022 addition of suicidality to the label are seen as belated responses.

The article suggests hundreds of thousands of users may have suffered depression and hundreds died by suicide, indicating significant potential for litigation and reputational damage for manufacturers like Merck (MRK) and Organon (OGN). Brezis criticizes the industry's "strategic silence" and the FDA's slow response to a black-box warning petition, which could expose both entities to increased scrutiny and legal liabilities. The drug's cosmetic classification may have contributed to its lack of intense post-marketing scrutiny.

This situation underscores critical gaps in pharmaceutical post-approval monitoring, especially for non-essential medications. Brezis advocates for immediate reforms, including suspending cosmetic marketing of finasteride and mandating rigorous post-approval studies, which could set a precedent for stricter regulatory oversight across the broader healthcare and biotech sector. Such reforms could increase R&D costs and time-to-market for new drugs, particularly those with cosmetic applications.

Key Decisions for Investors

• Monitor potential legal developments and class-action lawsuits against Merck (MRK) and Organon (OGN) related to finasteride's psychiatric side effects, as these could impact financial performance and stock valuations.
• Evaluate the broader implications for pharmaceutical companies with cosmetic or non-essential drugs, as regulatory scrutiny and post-market surveillance requirements may intensify, potentially increasing compliance costs and impacting market access.
• Assess the risk of increased regulatory intervention in drug approval and monitoring processes across the healthcare sector, which could affect future drug development timelines and profitability for new products.